KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 73,649 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 73,649 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, February 7th. The stock was acquired at an average price of $9.29 per share, for a total transaction of $684,199.21. Following the completion of the acquisition, the insider now owns 5,086,445 shares in the company, valued at approximately $47,253,074.05. The trade was a 1.47 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par acquired 4,137 shares of KalVista Pharmaceuticals stock. The shares were bought at an average cost of $9.14 per share, for a total transaction of $37,812.18.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The stock was bought at an average cost of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The shares were bought at an average cost of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ KALV traded up $0.08 during trading hours on Tuesday, reaching $9.27. The stock had a trading volume of 239,790 shares, compared to its average volume of 293,951. The business’s fifty day moving average price is $8.75 and its two-hundred day moving average price is $10.58. The firm has a market cap of $458.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. Equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on KALV. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Bank of America assumed coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $23.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of KalVista Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock worth $19,102,000 after purchasing an additional 104,716 shares during the period. Intech Investment Management LLC raised its stake in KalVista Pharmaceuticals by 58.5% in the fourth quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company’s stock worth $146,000 after buying an additional 6,349 shares in the last quarter. AlphaQuest LLC lifted its holdings in KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company’s stock worth $150,000 after buying an additional 2,588 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 2,043 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 1,319 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).